Abstract 341P
Background
The three most famous NUP214-associated gene rearrangements found in leukemia patients are SET::NUP214, NUP214::ABL1, and DEK::NUP214. Regardless of the NUP214’s partner gene or disease type, one common feature NUP214 rearrangements have in common is their association with resistance to treatment and poor prognosis. However, numerous mouse model experiments have shown that NUP214 rearrangement alone is insufficient for, or at least inefficient at, leukemogenesis. Therefore, identification of concurrent mutations as well as sensitive detection of these fusion genes are important for accurate assessment and tailored management of leukemia patients.
Methods
To identify patients with NUP214 gene rearrangement, RNA sequencing results of diagnostic bone marrow aspirates were retrospectively reviewed. Concurrent targeted next generation sequencing results as well as the patients’ demographics, karyotype, and flow cytometry information were also reviewed.
Results
A total of ten patients harboring NUP214 gene rearrangement were identified, among which four had SET: NUP214, three had DEK: NUP214, and three had NUP214: ABL1. Their diagnosis varied depending on the fusion type. Concurrent gene mutations were found in all ten cases. PFH6 mutations was the most common (5/10) followed by WT1 (3/10), NOTCH1 (3/10), FLT3-ITD (3/10) NRAS (2/10), and EZH2 (2/10). One of these patients was the world’s second case of NUP214: ABL1-positive AML.
Conclusions
We have shown the patient characteristics and concurrent test results of ten NUP214-rearranged leukemia patients. Since these gene rearrangements can serve as potential minimal residual disease markers as well as therapeutic targets, we hope our elucidation of the context in which they were discovered will help future research in regard to tailored monitoring and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract